STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 701–800 of 1,004
The role of programmed death receptor (PD‐)1/PD‐ligand (L)1 in periodontitis and cancer
Groeger, S. E., & Meyle, J. (2024) · Periodontology 2000 · doi:10.1111/prd.12548 · Cited by 20
Lou, B., Guo, M., Zheng, T., Liu, J., Wang, C., Chen, T., Chen, F., Fan, X., Gao, S., Xiao, L., et al. (2024) · Immunology · doi:10.1111/imm.13770 · Cited by 24
A muti-modal feature fusion method based on deep learning for predicting immunotherapy response
Li, X., Feng, X., Zhou, J., Luo, Y., Chen, X., Zhao, J., Chen, H., Xiong, G., & Luo, G. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111816 · Cited by 21
Silva, M. D., Itchins, M., & Pavlakis, N. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.87 · Cited by 19
“This incidence of irAEs is comparable to those reported with other anti-PD1/PDL1 therapies in related trials (15-19).”
BackgroundResultBiomarkers of immunotherapy in non‑small cell lung cancer (Review)
Wang, L., Hu, Y., Wang, S., Shen, J., & Wang, X. (2020) · Oncology Letters · doi:10.3892/ol.2020.11999 · Cited by 21
“Skoulidis et al (114) reported that patients with KRAS‐mutated lung adenocarcinoma (7.”
BackgroundInfluentialFricke, J., Mambetsariev, I., Pharaon, R. R., Subbiah, S. P., Rajurkar, S. P., & Salgia, R. (2020) · Medicine · doi:10.1097/md.0000000000022323 · Cited by 18
“5 months).([18]) In a larger cohort looking at 377 patients with metastatic nonsquamous NSCLC treated with pembrolizumab, platinum-doublet chemotherapy (carboplatin or cisplatin), and pemeterexed, 102 patients harboring an STK11 genomic alteration were associated with significant differences in ORR (32.”
BackgroundMolecular Features and Clinical Management of Hereditary Gynecological Cancers
Ueki, A., & Hirasawa, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249504 · Cited by 20
“Abbreviations ACMG American College of Medical Genetics and Genomics DICER1 Ribonuclease III; double-stranded RNA-specific endoribonuclease EMA European Medicines Agency FDA Food and Drug Administration HBOC hereditary breast and ovarian cancer syndrome HRD homologous recombination deficiency HRR homologous recombinat…”
BackgroundInfluentialSzlosarek, P. W., Wimalasingham, A. G., Phillips, M. M., Hall, P. E., Chan, P. Y., Conibear, J., Lim, L., Rashid, S., Steele, J. P. C., Wells, P., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4196 · Cited by 19
Wei, R., Quan, J., Li, S., Liu, H., Guan, X., Jiang, Z., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.724860 · Cited by 24
Schlauch, D., Fu, X., Jones, S. F., Burris, H. A., Spigel, D. R., Reeves, J. A., & McKenzie, A. J. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00008 · Cited by 20
“Conversely, NSCLC tumors harboring mutations in STK11 are associated with lack of response to single-agent CPI.(23) These examples notwithstanding, discrete mutations within a tumor that correspond to response to CPIs remain an area of intense investigation.”
BackgroundResultInfluentialSelf-citationBenzekry, S., Grangeon, M., Karlsen, M., Alexa, M., Bicalho-Frazeto, I., Chaleat, S., Tomasini, P., Barbolosi, D., Barlési, F., & Greillier, L. (2021) · Cancers · doi:10.3390/cancers13246210 · Cited by 46
“It was initially not linked with poor response to ICIs [39], but a better response when mutated was shown in 2019 [40], whereas the co-occurring genomic alteration of K-RAS and STK11/LKB1 was associated with a primary resistance to PD1 axis blockade [41].”
BackgroundFrille, A., Boeschen, M., Wirtz, H. R. W., Stiller, M., Bläker, H., & von Laffert, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357583 · Cited by 25
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 21
Zhao, W., Nguyen, T. T., Bhagwat, A., Kumar, A., Giotti, B., Kepecs, B., Weirather, J. L., Mahadevan, N. R., Segerstolpe, Å., Dolasia, K., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01053-7 · Cited by 31
“…17–20 and TP53 mutations have been associated with increased expression of PDL1 and improved response to anti-PD1 therapy in human lung adenocarcinoma (LUAD) 21–26 , motivating us to investigate TME differences in persons with LUAD with TP53 -mutant ( TP53 mut ) versus wild-type ( TP53 WT ) tumors.”
Self-citationDonnelly, L. L., Hogan, T. C., Lenahan, S. M., Nandagopal, G., Eaton, J. G., Lebeau, M. A., McCann, C., Sarausky, H. M., Hampel, K. J., Armstrong, J. D., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab104 · Cited by 18
“Given the clinical data demonstrating patients with KRAS-driven NSCLC lacking functional STK11 respond poorly to anti-PD-1 monotherapy (10), our analyses of un- and under-characterized STK11 variants provides critical pre-clinical evidence that can be used to help guide oncologic care for the ~15 000 patients diagnose…”
InfluentialTargeting KRAS G12C mutation in lung adenocarcinoma
Rohatgi, A., & Govindan, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.021 · Cited by 18
Sun, Y., Li, Z., Jian, H., Xia, L., & Lü, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144003 · Cited by 19
Wu, X., Deng, Z., & Zhao, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967076 · Cited by 23
“However, not all patients show an immune response to immunotherapy (30, 39) or develop drug resistance after treatment (68, 69).”
BackgroundPosttranslational regulation of liver kinase B1 in human cancer
Hu, L., Liu, M., Tang, B., Li, Q., Pan, B., Xu, C. S., & Lin, H. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104570 · Cited by 19
Smith-Oliver, M. R., Wang, Y., D’Agostino, R., Liu, Y., Ruiz, J., Lycan, T. W., Oliver, G., Miller, L. D., Topaloĝlu, Ü., Pinkney, J., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00373-0 · Cited by 23
Adaptive Cancer Therapy in the Age of Generative Artificial Intelligence
Derbal, Y. (2024) · Cancer Control · doi:10.1177/10732748241264704 · Cited by 19
“The alteration status of KRAS, TP53 and STK11/LKB1 may also be used to inform about T-cell exclusion or in fl ammation of the TME, and resistance to immune PD-1 inhibitors, 99 as well as provide a correlate for PD-L1 expression.”
BackgroundStrategies for engineering oncolytic viruses to enhance cancer immunotherapy
Yin, Z. S., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1450203 · Cited by 18
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma
Gibert, J., Clavé, S., Hardy-Werbin, M., Taus, Á., Rocha, P., Longarón, R., Piquer, G., CHAIB-OUKADOUR, I., Carcereny, E., Morán, T., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.003 · Cited by 16
Yang, R. K., Qing, Y., Jelloul, F. Z., Routbort, M. J., Wang, P., Shaw, K. R. M., Zhang, J., Lee, J., Medeiros, L. J., Kopetz, S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27466 · Cited by 23
“For example, in KRAS-mutant lung adenocarcinoma, STK11/LKB1 mutation is associated with resistance to ICB treatment [29].”
BackgroundSelf-citationBiomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Viteri, S. A., & Khosravi‐Shahi, P. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.006 · Cited by 19
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 19
Lam, V. K. L., & Zhang, J. J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.68 · Cited by 17
“, EGFR, ALK) and STK11 ideally should be stratified in any comparison of clinical outcomes (22,23).”
BackgroundSelf-citationRosner, S., Connor, S. C., Sanber, K. S., ZAHURAK, M. L., Zhang, T., Gurumurthy, I., Zeng, Z., Presson, B., Singh, D., Rayes, R. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2983 · Cited by 21
Radon Exposure and Cancer Risk: Assessing Genetic and Protein Markers in Affected Populations
Kashkinbayev, Y., Kazhiyakhmetova, B., Altaeva, N., Bakhtin, M., Tarlykov, P., Saifulina, E., Aumalikova, M., Ibrayeva, D., & Bolatov, A. (2025) · Biology · doi:10.3390/biology14050506 · Cited by 20
“A study by Skoulidis et al. (2018) highlighted the importance of genomic profiling in guiding therapy, demonstrating that patients with specific genetic alterations showed differential responses to targeted therapies and immunotherapies [66].”
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
Krzyżanowska, N., Krawczyk, P. A., Wojas‐Krawczyk, K., Kucharczyk, T., & Milanowski, J. (2022) · Cells · doi:10.3390/cells11203280 · Cited by 18
“TP53 co-mutation was favorable also in patients without PD-L1 expression (Table 2) [29].”
BackgroundKRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Rosell, R., Lewintre, E. J., Cao, P., Cai, X., Xing, B., Ito, M., Gomez-Vazquez, J. L., Marco-Jordán, M., Fariñas, S. C., Cardona, A. F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01667-x · Cited by 18
Current perspectives of KRAS in non-small cell lung cancer
Harris, E., & Thawani, R. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101106 · Cited by 18
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 19
Daley, B. R., Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Gerlach, D., Hofmann, M. H., Kostyrko, K., LaMorte, J. P., Linke, A. J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3256 · Cited by 22
Kwon, M., Hong, J. Y., Kim, S. T., Kim, K., & Lee, J. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152947 · Cited by 17
Self-citationXiang, L., Fu, X., Wang, X., Li, W., Zheng, X., Nan, K., & Tian, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.559896 · Cited by 22
“In KRAS-mutant LUAD, KRAS with STK11 co-mutation was reported to facilitate immune escape and resistance to anti-PD1 therapy and to mostly be an “immune desert” phenotype (26, 27).”
BackgroundYu, L., Qiao, R., Xu, J., Han, B., & Zhong, R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119022 · Cited by 16
Fernandes, M. G. O., Martins, N. A., Machado, J. C., Costa, J. L., & Hespanhol, V. P. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02382-0 · Cited by 18
Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Park, J. J.-Y., Codina, A., Ye, L., Lam, S. Z., Guo, J., Clark, P. R., Zhou, X., Peng, L., & Chen, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01389-y · Cited by 15
Hasegawa, T., Yanagitani, N., Ninomiya, H., Sakamoto, H., Tozuka, T., Yoshida, H., Amino, Y., Uematsu, S., YOSHIZAWA, T., Ariyasu, R., et al. (2020) · In Vivo · doi:10.21873/invivo.12131 · Cited by 15
Low prevalence of HTLV-II in Mayan Indians in the Yucatan Peninsula, Mexico.
Góngora-Biachi, R. A., Lal, R. B., Rudolph, D. L., Castro-Sansores, C. J., González-Martínez, P., & Pavía‐Ruz, N. (1997) · PubMed · Cited by 16
Shi, R., Sun, J., Zhou, Z., Shi, M., Wang, X., Gao, Z., Zhao, T., Li, M., & Shu, Y. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00842-8 · Cited by 18
Niknafs, N., Najjar, M., Dennehy, C., Stouras, I., & Anagnostou, V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0824 · Cited by 22
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Keenan, B. P., Yadav, M., Ansstas, G., Fabrizio, D. A., Murugesan, K., Montesion, M., Niyogi, D. G., Mellman, I., & Melero, I. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1239 · Cited by 26
Self-citationTumor mutational burden as predictive factor of response to immunotherapy
González‐Cao, M., Viteri, S., Karachaliou, N., Aguilar, A., Garcia, J. J., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.03 · Cited by 17
Kwack, W. G., Shin, S. Y., & Lee, S. H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s272013 · Cited by 17
Shi, W., & Zhao, W. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001090 · Cited by 15
“Some oncogenes and anti-oncogenes such as EGFR and STK11 are implicated in ICI resistance.([28,29]) Moreover, a previous study reported that the diversity of the gut microbiome, which easily changes upon the administration of antibiotics, may be involved in ICI resistance.”
BackgroundBao, J., Närhi, K. M., Teodòsio, A., Hemmes, A., Linnavirta, N., Mäyränpää, M. I., Salmenkivi, K., Quesne, J. P. C. L., & Verschuren, E. W. (2021) · The Journal of Pathology · doi:10.1002/path.5733 · Cited by 15
Co-dependencies in the tumor immune microenvironment
Chen, P., & Dey, P. (2022) · Oncogene · doi:10.1038/s41388-022-02406-7 · Cited by 15
“In addition to the mutations of PTEN and EGFR, loss of LKB1 has been identified as the prevalent genomic driver for antiPD-1 therapy resistance in Kras-mutated lung adenocarcinoma mouse model and patients [134].”
BackgroundZhou, S., Cai, Y., Xu, Z., Peng, B., Liang, Q., Peng, J., & Yan, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.964362 · Cited by 16
“It points out that the combination of immunotherapy will be used in the subset of LUAD group (37).”
MethodTriple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Corte, C. M. D., Ciaramella, V., Ramkumar, K., Vicidomini, G., Fiorelli, A., Nardone, V., Cappabianca, S., Cozzolino, I., Marino, F. Z., Guida, G. D., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03730-y · Cited by 16
“Clinical data have shown the potentiality of genomic markers to negatively predict immunotherapy response as with oncogene-addicted NSCLCs (EGFR, ALK, ROS1 mutant) and KRAS/STK11 mutant tumors [1, 2].”
BackgroundSelf-citationImmunotherapy through the Lens of Non-Small Cell Lung Cancer
Stanley, R., Flanagan, S., Reilly, D. E. O., Kearney, E., Naidoo, J., & Dowling, C. M. (2023) · Cancers · doi:10.3390/cancers15112996 · Cited by 21
Li, H., Guo, H., Huang, Q., Wang, S., Li, X., & Qiu, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02563-7 · Cited by 15
“Despite significant advancements in therapeutic approaches, including targeted therapy, immunological treatments, and the discovery of novel biomarkers, the prognosis for LUAD patients remains poor [3–6].”
BackgroundUnraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
Song, L., Gong, Y., Wang, E., Huang, J., & Li, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231210274 · Cited by 21
“102,103 There were also reports on the poor effectiveness of ICIs in LUAD with ALK rearrangement.”
BackgroundTherapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer
Plaugher, D. R., Childress, A. R., Gosser, C. M., Esoe, D.-P. I., Naughton, K. J., Hao, Z., & Brainson, C. F. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217281 · Cited by 20
Lv, L., Miao, Q., Zhan, S., Chen, P., Liu, W., Lv, J., Yan, W., Wang, D., Liu, H., Yin, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009444 · Cited by 22
Amato, L., Rosa, C. D., Guida, G. D., Sepe, F., Ariano, A., Capaldo, S., Haq, F. U., Liello, A. D., Tuccillo, C., Lucà, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07636-7 · Cited by 19
“Additionally, STK11/LKB1 inactivation is a major genetic driver of primary resistance to anti-PD-1 agents and co-mutation of STK11 and KEAP1 genes has been correlated to higher sensitivity to dual immunotherapy with anti-CTLA4 and anti-PD-1 agents versus anti-PD1 alone [5, 6].”
The 5-Ws of immunotherapy in head and neck cancer
Botticelli, A., Mezi, S., Pomati, G., Cerbelli, B., Rocco, C. D., Amirhassankhani, S., Sirgiovanni, G., Occhipinti, M. A., Napoli, V. M., Emiliani, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103041 · Cited by 15
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Nadal, E., Heeke, S., Benzaquen, J., Vilariño, N., Navarro-Martín, A., Azuara, D., Varela, M., Otto, J., Baixeras, N., Shahbazian, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00174 · Cited by 17
Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico
Zheng, R., Yin, Z., Alhatem, A., Lyle, D., You, B., Jiang, A. S., Liu, D., Jobbágy, Z., Wang, Q., Aisner, S. C., et al. (2020) · Cancers · doi:10.3390/cancers12123492 · Cited by 19
Reconstruction and Analysis of the Immune-Related LINC00987/A2M Axis in Lung Adenocarcinoma
Ma, J., Lin, X., Wang, X., Min, Q.-Q., Wang, T., & Tang, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.644557 · Cited by 16
“Previous research has identified that in KRAS-mutant LUAD, STK11/LKB1 mutations were major drivers of resistance to PD-1 blockade (Koulidis et al., 2018).”
BackgroundIzumi, M., Sawa, K., Oyanagi, J., Noura, I., Fukui, M., Ogawa, K., Matsumoto, Y., Tani, Y., Suzumura, T., Watanabe, T., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101102 · Cited by 15
Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01221-3 · Cited by 19
“Current studies have shown that the patients with EGFR, STK11, ALK, and other gene mutations are less effective in receiving ICIs therapy, while the patients with KRAS mutations have better therapeutic effects when receiving ICIs therapy, but the response of different mutation subtypes to immunotherapy is not consiste…”
BackgroundResearch progress on the therapeutic effect and mechanism of metformin for lung cancer (Review)
Han, P., Zhou, J., Xiang, J., Liu, Q., & Sun, K. (2022) · Oncology Reports · doi:10.3892/or.2022.8440 · Cited by 18
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
Bungaro, M., Novello, S., & Passiglia, F. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01033-4 · Cited by 16
Wang, Y., Huang, S., Feng, X., Xu, W., Luo, R., Zhu, Z., Zeng, Q., & He, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145128 · Cited by 15
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 17
Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology
Ferro, M., Crocetto, F., Jannello, L. M. I., Contieri, R., Falagario, U. G., Veccia, A., Marchioni, M., Tătaru, O. S., Barone, B., Fallara, G., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104862 · Cited by 19
Sun, X., Cai, X.-T., Li, S., Pi, R., Guo, Z.-Q., Jiang, J., Wang, P., Xiong, J., Liu, Z., Rong, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102291 · Cited by 19
Liu, Y., Department of Colorectal and Anal Surgery, T. F. H. O. J. U., Cheng, L., Song, X., Li, C., Zhang, J., Wang, L., Department of Orthopedics, T. F. H. O. J. U., & Department of Hepatobiliary and Pancreatic Surgery, T. F. H. O. J. U. (2022) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2022010 · Cited by 14
Self-citationAlmotlak, A. A., Farooqui, M., Soloff, A. C., Siegfried, J. M., & Stabile, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010081 · Cited by 15
“KRAS mutant lung cancers are highly dependent on the HER network, especially HER2 and HER3 [12,13], and KRAS mutant lung cancer patients harboring TP53 co-mutations were shown to have the best objective response rate to PD-1 blockade compared to those with STK11/LKB1 co-mutations or KRAS only mutations in the CheckMat…”
BackgroundClinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC
Cooper, A. J., Muzikansky, A., Lennerz, J., Narinesingh, F., Mino-Kenudson, M., Hung, Y. P., Piotrowska, Z., Dagogo-Jack, I., Sequist, L. V., Gainor, J. F., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100390 · Cited by 14
“In addition, the relatively low level of PD-L1 expression found in the KRAS G12D/STK11-mutated cohort recapitulates what has been revealed with other cohorts.(7,26,27)”
ResultSelf-citationLenahan, S. M., Sarausky, H. M., Deming, P. B., & Seward, D. J. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00687-y · Cited by 23
Pharmacological agents targeting drug-tolerant persister cells in cancer
Chen, Y., Gowda, K., Amin, S., Schell, T. D., Sharma, A. K., & Robertson, G. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107163 · Cited by 19
Xu, K., Lu, W., Yu, A., Wu, H., & He, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12130-y · Cited by 20
Torres-Mejia, E., Weng, S., Whittaker, C. A., Nguyen, K. B., Duong, E., Yim, L., & Spranger, S. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0184 · Cited by 17
Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
Kwon, D., Kim, B., Shin, H. C., Kim, E. J., Ha, S. Y., Jang, K., Kim, S. T., Lee, J., Kang, W. K., Park, J. O., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.017 · Cited by 14
“[33,34] We observed STK11 alterations in 3 CRCs, 2 GCs, and 1 MM case.”
BackgroundSelf-citationQin, Y., Yu, M., Zhou, L., Jiang, L., & Huang, M. (2020) · Immunotherapy · doi:10.2217/imt-2019-0166 · Cited by 15
Schatz, S., Falk, M., Jóri, B., Ramdani, H., Schmidt, S., Willing, E., Menon, R., Groen, H. J. M., Diehl, L., Kröger, M., et al. (2020) · Cancers · doi:10.3390/cancers12061685 · Cited by 15
“Recent publications suggest that STK11 and KEAP1 mutations might be associated with an inferior response to IO [34,35].”
BackgroundChen, J. A., & Riess, J. W. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00750-y · Cited by 16
“Furthermore, STK11/LKB1 is associated with PD-L1-negative tumors despite intermediate or high TMB and demonstrates lower T cell immunogenicity as measured through tumor-infiltrating lymphocytes and gene signatures [60].”
BackgroundResultInfluentialMa, S.-C., Zhu, H., Wang, J., Zhang, Y.-P., Guo, X., Long, L.-L., Guo, Z.-Q., Wu, D., Dong, Z., & Bai, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666145 · Cited by 15
Self-citationTanaka, I., & Morise, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010245 · Cited by 16
“Zhang et al. reported that there were no significant differences in PD-L1 expression between NSCLC with BRAF mutation and wild-type, whereas BRAF mutation was associated with higher TMB compared with BRAF wildtype [86].”
BackgroundInfluentialResistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
Li, Y., Hu, L., Peng, X., Xu, H., Tang, B., & Xu, C. S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.102 · Cited by 16
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
Cattolico, C., Bailey, P., & Barry, S. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816517 · Cited by 18
Rare Hereditary Gynecological Cancer Syndromes
Watanabe, T., Soeda, S., Endo, Y., Okabe, C., Sato, T., Kamo, N., Ueda, M., Kojima, M., Furukawa, S., Nishigori, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031563 · Cited by 16
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 20
“However, the KRAS G12C mutation can be associated with STK11 and/or KEAP1 mutations and show a low response to immunotherapy [89,91,92,104,181,182].”
BackgroundBodor, J. N., Bauman, J. R., Handorf, E. A., Ross, E. A., Clapper, M. L., & Treat, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04089-9 · Cited by 14
“For instance, among KRAS-mutant disease, tumors with a co-mutation in serine/threonine kinase 11/liver kinase B1 (STK11/LKB1) exhibit greater primary resistance to immune-based therapies, including in tumors that are PD-L1 positive (Skoulidis et al. 2018).”
BackgroundTargeting KRAS : Crossroads of Signaling and Immune Inhibition
Kato, S., Fujiwara, Y., & Hong, D. S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-5 · Cited by 15
Epistasis and evolutionary dependencies in human cancers
Mina, M., Iyer, A., & Ciriello, G. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101989 · Cited by 14
Zhan, X., Feng, S., Zhou, X., Liao, W., Zhao, B., Yang, Q., Tan, Q., & Shen, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1047435 · Cited by 15
“Generally, LUAD often has high tumor mutational burden (TMB) and immunogenicity characteristics (Skoulidis et al., 2018).”
BackgroundCavallaro, D., Guerrieri, M., Cattelan, S., Fabbri, G., Croce, S., Armati, M., Bennett, D., Fossi, A., Voltolini, L., Luzzi, L., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10123277 · Cited by 14
Numakura, K., Horikawa, Y., Kamada, S., Koizumi, A., Nara, T., Chiba, S., Kanda, S., Saito, M., Narita, S., Inoue, T., et al. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1887 · Cited by 15
“It has been reported that long-term application of anti-PD1 antibody can also cause drug resistance (19).”
Treatment options after first-line immunotherapy in metastatic NSCLC
Santos, E. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1738930 · Cited by 14
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., & Liu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665265 · Cited by 13
Dagogo‐Jack, I., Mitchell, O. D., Codd, E. M., Li, A., Mitchell, D. R., Flynn, S. E., Sivamanoharan, N., Reeves, P. M., Poznansky, M. C., Valiev, I., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.018 · Cited by 20
Cheng, T., Wu, Y., & Wu, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616872 · Cited by 14
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
“175 176–180 Activation of this pathway has been shown to cause T cell exclusion in lung cancer.”
Rojas, F. R., Parra, E. R., Wistuba, I. I., Haymaker, C., & Soto, L. M. S. (2022) · Cancers · doi:10.3390/cancers14112775 · Cited by 21
“In addition, the STK11 mutation has emerged as a possible biomarker predictor of resistance to PD‐1 and PD‐L1 inhibition [78,79].”
BackgroundSelf-citation
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.